Markets:

Overview

News

Currencies

International

Treasuries

Cidara Therapeutics, Inc. - Common Stock (NQ:CDTX)

220.36 -0.14 (-0.06%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Cidara Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Is This Pharmaceutical Giant a Buy After a Major Acquisition? ↗

Today 12:25 EST

The rebound is well underway.

Via The Motley Fool

Topics Death

3 Non-AI Stocks to Buy: MRK, UPS, CVX ↗

November 30, 2025

There are plenty of potential winners outside the world of AI.

Via The Motley Fool

Topics Artificial Intelligence

Should You Buy This Blue Chip Pharmaceutical Stock That Just Popped 3.8%? ↗

November 29, 2025

The struggling pharmaceutical giant is showing signs of life.

Via The Motley Fool

Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million ↗

November 20, 2025

Bain Capital added more than 12.4 million shares of HeartFlow stock in the thrid quarter

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

Cidara Therapeutics Stock Rockets Over 700% This Year — Then Wall Street Turns Neutral On Merck Takeover ↗

November 17, 2025

Via Stocktwits

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer ↗

November 20, 2025

Bain Capital's bet on Cidara Therapeutics stocks has paid off in a big way

Via The Motley Fool

Topics Regulatory Compliance

Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs? ↗

November 20, 2025

The pharmaceutical giant's post-Keytruda plans continue to take shape.

Via The Motley Fool

Topics Intellectual Property

Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. ↗

November 20, 2025

Shares in the biotech company have surged on news of a big pharma takeover.

Via The Motley Fool

Biotech Stock Gets Booted in Latest Fund Update ↗

November 19, 2025

Bain Capital sold its entire stake in Nuvalent stock during the third quarter.

Via The Motley Fool

Topics Regulatory Compliance

Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock ↗

November 19, 2025

Bain Capital completely exited its position in Disc Medicine stock during the third quarter

Via The Motley Fool

Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything ↗

November 18, 2025

Via MarketBeat

Why Bain Capital Is Selling Shares of This Biotech Stock Now ↗

November 18, 2025

Bain Capital sold $20 million worth of Pharvaris stock during the third quarter.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover ↗

November 17, 2025

One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks.

Via The Motley Fool

Top 2 Health Care Stocks That May Fall Off A Cliff This Month ↗

November 17, 2025

Via Benzinga

Top movers analysis one hour before the close of the markets on 2025-11-14: top gainers and losers in today's session. ↗

November 14, 2025

Here are the top movers in Friday's session, showcasing the stocks with significant price changes.

Via Chartmill

Which stocks are moving on Friday? ↗

November 14, 2025

Intrigued by the market activity in the middle of the day on Friday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

12 Health Care Stocks Moving In Friday's Intraday Session ↗

November 14, 2025

Via Benzinga

Gold Tumbles Over 2%; Cidara Therapeutics Shares Spike Higher ↗

November 14, 2025

Via Benzinga

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

November 14, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.

Via Chartmill

Merck Swoops In On Buyout Bonanza With A $9.2 Billion Cidara Therapeutics Deal ↗

November 14, 2025

The company is getting deeper into the antiviral space, buying a company working on a long-acting drug to protect against flu.

Via Investor's Business Daily

Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday ↗

November 14, 2025

Via Benzinga

Nasdaq Dips Over 300 Points; Applied Materials Posts Upbeat Q4 Earnings ↗

November 14, 2025

Via Benzinga

Merck Makes Big Bet On Flu Protection With Cidara Buyout ↗

November 14, 2025

Merck (NYSE: MRK) to acquire Cidara (NASDAQ: CDTX) for $9.2 billion, diversifying its portfolio with CD388.

Via Benzinga

Discover the top movers in Friday's pre-market session. ↗

November 14, 2025

Discover the top movers in Friday's pre-market session and stay informed about market dynamics.

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

November 14, 2025

Via Benzinga

Merck To Buy Cidara In $9.2B Deal To Strengthen Antiviral Portfolio ↗

November 14, 2025

With the new deal, Merck would gain access to CD388, currently in late-stage development, and designed to prevent influenza infection in individuals at higher risk of influenza complications.

Via Stocktwits

Topics Intellectual Property

Why RLX Technology Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket ↗

November 14, 2025

Via Benzinga

Why Is Cidara Therapeutics (CDTX) Stock Trending Overnight? ↗

November 14, 2025

Cidara Therapeutics shares jumped over 42% in after-hours trading following a 13D filing and Phase 3 enrollment milestone.

Via Benzinga

Cidara Therapeutics Stock Soars 42% After-Hours On Merck Buyout Buzz — Retail Traders Eye A Potential Blowout Premium ↗

November 13, 2025

Via Stocktwits

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.